July 2026 in “Journal of Investigative Dermatology” GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
May 2026 in “Reviews in Endocrine and Metabolic Disorders” This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.
July 2026 in “Science Progress” This review reports significant improvements in hidradenitis suppurativa symptoms and comorbid conditions with GLP-1-receptor-agonists, suggesting potential as a multimodal treatment strategy.
March 2026 in “Frontiers in Medicine” This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.
In this retrospective case series, therapeutic responses to immunomodulatory and incretin-based therapies for Dercum's disease showed considerable individual variation, suggesting these treatments might be exploratory options when surgery isn't feasible, though further controlled studies are needed for definitive conclusions.